GlassScriptPhysician profile
Tina Nigam
NPI 1619437084
$4,456.67
in general payments reported to CMS, 2019-2025
36 companies · $3,169 in 2025
The $3,169 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,288 · 2025: $3,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,321 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,320.88 |
| Education | $135.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.61 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $360.22 | 2024-2025 | |
| Pfizer INC. | $296.79 | 2024-2025 | |
| Ucb, INC. | $283.86 | 2024-2025 | Briviact, Rystiggo, Nayzilam |
| Mallinckrodt Hospital Products INC. | $264.68 | 2024-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $236.49 | 2024-2025 | Hyqvia |
| Lilly USA, LLC | $225.86 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Sk Life Science, INC. | $189.06 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $174.71 | 2024 | Zeposia |
| Janssen Biotech, INC. | $165.14 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $152.64 | 2024-2025 | Rexulti |
| Argenx US, INC. | $143.60 | 2024-2025 | Vyvgart Hytrulo |
| Emd Serono, INC. | $133.35 | 2025 | |
| Csl Behring | $130.11 | 2024-2025 | Hizentra |
| Celgene Corporation | $123.92 | 2024-2025 | Zeposia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $122.69 | 2025 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $120.75 | 2025 | Ponvory |
| Eisai INC. | $113.74 | 2025 | |
| Lundbeck LLC | $81.23 | 2024-2025 | Vyepti, Rexulti |
| Amgen INC. | $78.32 | 2025 | Uplizna |
| Mdd US Operations, LLC | $73.07 | 2025 | Gocovri |
| Biogen, INC. | $67.99 | 2024-2025 | Tysabri, Leqembi, Vumerity |
| Alexion Pharmaceuticals, INC. | $62.06 | 2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $61.71 | 2025 | Crexont |
| Microtransponder, INC. | $60.61 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $56.30 | 2024-2025 | Nuplazid |
| Genentech USA, INC. | $51.31 | 2024 | Ocrevus, Ocrevus Zunovo |
| Cycle Pharmaceuticals INC | $43.65 | 2024-2025 | Tascenso Odt, Bafiertam |
| Teva Pharmaceuticals USA, INC. | $38.67 | 2024-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $35.80 | 2025 | |
| Tanabe Pharma America, INC. | $29.75 | 2025 | Radicava |
| Neurocrine Biosciences, INC. | $25.63 | 2025 | |
| Jazz Pharmaceuticals INC. | $25.30 | 2024 | |
| Averitas Pharma INC. | $22.57 | 2025 | Qutenza |
| Neurelis, INC. | $18.81 | 2024 | Valtoco |
| Scilex Pharmaceuticals INC. | $18.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Nigam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.